Details for Patent: 10,071,985

Which drugs does patent 10,071,985 protect, and when does it expire?

Patent 10,071,985 protects SUNLENCA and YEZTUGO and is included in four NDAs.

This patent has ninety-five patent family members in forty-four countries.

Summary for Patent: 10,071,985

Title:	Therapeutic compounds
Abstract:	The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Inventor(s):	Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. SAITO, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
Assignee:	Gilead Sciences Inc
Application Number:	US15/680,041
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,071,985

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes			Y	Y

International Family Members for US Patent 10,071,985

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3347352		CA 2022 00052	Denmark
European Patent Office	3347352		301212	Netherlands
European Patent Office	3347352		PA2023501	Lithuania
European Patent Office	3347352		122022000082	Germany
European Patent Office	3347352		2022C/561	Belgium
European Patent Office	3347352		CR 2022 00052	Denmark